Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Mar. 06, 2017 | Jun. 30, 2016 | |
Document Information [Line Items] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2016 | ||
Document Fiscal Year Focus | 2,016 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | Neurotrope, Inc. | ||
Entity Central Index Key | 1,513,856 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Public Float | $ 15,854,174 | ||
Trading Symbol | NTRP | ||
Entity Common Stock, Shares Outstanding | 7,448,823 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 25,773,533 | $ 11,230,637 |
Prepaid expenses | 138,711 | 1,489,851 |
Subscription receivable | 0 | 2,761 |
TOTAL CURRENT ASSETS | 25,912,244 | 12,723,249 |
Fixed Assets, net of accumulated depreciation | 55,198 | 59,175 |
TOTAL ASSETS | 25,967,442 | 12,782,424 |
CURRENT LIABILITIES | ||
Accounts payable | 2,167,413 | 449,875 |
Accrued expenses | 190,744 | 141,525 |
Accrued expenses - related party | 4,609 | 389,058 |
Note payable | 0 | 10,511 |
TOTAL CURRENT LIABILITIES | 2,362,766 | 990,969 |
Commitments and contingencies | ||
SHAREHOLDERS' DEFICIT | ||
Common stock - 12,500,000 shares authorized, $.0001 par value; 6,754,547 shares issued and outstanding at December 31, 2016; 1,536,570 shares issued and outstanding at December 31, 2015 | 676 | 154 |
Additional paid-in capital | 73,648,737 | 27,700,651 |
Accumulated deficit | (50,044,737) | (27,724,224) |
TOTAL SHAREHOLDERS' DEFICIT | 23,604,676 | (23,419) |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | 25,967,442 | 12,782,424 |
Series B Convertible Redeemable Preferred Stock [Member] | ||
CONVERTIBLE REDEEMABLE PREFERRED STOCK | ||
Convertible redeemable preferred stock, Series B, $.0001 par value, 333,333 shares authorized; 262,349.4 shares issued and outstanding at December 31, 2015. Liquidation preference of $15,740,963 plus dividends accruable of $279,824 at December 31, 2015. | $ 0 | $ 11,814,874 |
Consolidated Balance Sheets _Pa
Consolidated Balance Sheets [Parenthetical] - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 12,500,000 | 12,500,000 |
Common stock, shares issued | 6,754,547 | 1,536,570 |
Common stock, shares outstanding | 6,754,547 | 1,536,570 |
Series B Convertible Redeemable Preferred Stock [Member] | ||
Convertible redeemable preferred stock, par value (in dollars per share) | $ 0.0001 | |
Convertible redeemable preferred stock, shares authorized | 333,333 | |
Convertible redeemable preferred stock, shares issued | 262,349.4 | |
Convertible redeemable preferred stock, shares outstanding | 262,349.4 | |
Convertible redeemable preferred stock, Liquidation Preference, Value (in dollars) | $ 15,740,963 | |
Dividends Payable (in dollars) | $ 279,824 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
OPERATING EXPENSES: | ||
Research and development - related party | $ 1,028,915 | $ 2,023,595 |
Research and development | 5,603,989 | 2,180,263 |
General and administrative - related party | 59,500 | 804,022 |
General and administrative | 3,435,707 | 3,714,943 |
Stock-based compensation - related party | 752,695 | 175,752 |
Stock-based compensation | 2,051,832 | 547,182 |
TOTAL OPERATING EXPENSES | 12,932,638 | 9,445,757 |
OTHER INCOME: | ||
Interest income | 8,436 | 4,222 |
Net loss before income taxes | (12,924,202) | (9,441,535) |
Provision for income taxes | 0 | 0 |
Net loss | (12,924,202) | (9,441,535) |
Preferred Stock dividends | 0 | (279,824) |
Net loss attributable to common shareholders | $ (12,924,202) | $ (9,721,359) |
PER SHARE DATA: | ||
Basic and diluted loss per common share (in dollars per share) | $ (5.69) | $ (11.64) |
Basic and diluted weighted average common shares outstanding (in shares) | 2,272,000 | 835,200 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Shareholders' Deficit - USD ($) | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] |
Balance at Dec. 31, 2014 | $ (11,652,303) | $ 75 | $ 6,630,311 | $ (18,282,689) |
Balance (in shares) at Dec. 31, 2014 | 751,065 | |||
Conversion of preferred stock to common stock | 18,524,163 | $ 67 | 18,524,096 | 0 |
Conversion of preferred stock to common stock (in shares) | 667,594 | |||
Issuance of additional common stock upon Series A anti-dilution | 0 | $ 10 | (10) | 0 |
Issuance of additional common stock upon Series A anti-dilution (in shares) | 100,253 | |||
Stock based compensation | 722,934 | $ 0 | 722,934 | 0 |
Exercise of common stock warrants | 5,651 | $ 2 | 5,649 | 0 |
Exercise of common stock warrants (in shares) | 17,658 | |||
Issuance of common stock warrants | 1,817,671 | $ 0 | 1,817,671 | 0 |
Net loss | (9,441,535) | 0 | 0 | (9,441,535) |
Balance at Dec. 31, 2015 | (23,419) | $ 154 | 27,700,651 | (27,724,224) |
Balance (in shares) at Dec. 31, 2015 | 1,536,570 | |||
Conversion of preferred stock to common stock | 11,814,874 | $ 85 | 11,814,789 | 0 |
Conversion of preferred stock to common stock (in shares) | 847,371 | |||
Issuance of Common Stock in Private Placement | 21,759,717 | $ 383 | 21,759,334 | |
Issuance of Common Stock in Private Placement (in shares) | 3,828,754 | |||
Stock based compensation | 2,804,527 | $ 0 | 2,804,527 | 0 |
Exercise of common stock warrants | 173,179 | $ 54 | 173,125 | 0 |
Exercise of common stock warrants (in shares) | 541,189 | |||
Shares issued for stock split rounding | 662 | |||
Revaluation of investor warrants | 0 | 9,396,311 | (9,396,311) | |
Net loss | (12,924,202) | $ 0 | 0 | (12,924,202) |
Balance at Dec. 31, 2016 | $ 23,604,676 | $ 676 | $ 73,648,737 | $ (50,044,737) |
Balance (in shares) at Dec. 31, 2016 | 6,754,547 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (12,924,202) | $ (9,441,535) |
Adjustments to reconcile net loss to net cash used by operating activities | ||
Stock based compensation | 2,804,527 | 722,934 |
Depreciation expense | 6,923 | 6,270 |
Change in assets and liabilities | ||
Decrease (increase) in prepaid expenses | 1,351,140 | (1,392,778) |
Decrease (Increase) in subscription receivable | 2,761 | (2,761) |
Increase (decrease) in accounts payable | 1,717,538 | (328,878) |
Increase (decrease) in accrued expenses | 49,219 | (168,910) |
Total adjustments | 5,547,659 | (875,065) |
Net Cash Used in Operating Activities | (7,376,543) | (10,316,600) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Purchase of property and equipment | (2,946) | (11,827) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Issuance of common stock, net of transaction costs | 21,759,717 | 0 |
Issuance of preferred stock, net of transaction costs | 0 | 13,532,546 |
Proceeds from note payable | 0 | 28,904 |
Repayments on note payable | (10,511) | (18,394) |
Proceeds from exercise of common stock warrants | 173,179 | 5,651 |
Net Cash Provided by Financing Activities | 21,922,385 | 13,548,707 |
NET INCREASE IN CASH | 14,542,896 | 3,220,280 |
CASH AT BEGINNING OF YEAR | 11,230,637 | 8,010,357 |
CASH AT END OF YEAR | 25,773,533 | 11,230,637 |
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES: | ||
Dividend deemed from warrant revaluation | $ 9,396,311 | $ 0 |
Conversion of convertible redeemable preferred stock to common stock | 11,814,874 | 18,524,163 |
Accounts Payable [Member] | ||
Change in assets and liabilities | ||
Increase (Decrease) in Due to Related Parties, Total | $ 0 | $ (200,000) |
Accrued Liabilities [Member] | ||
Change in assets and liabilities | ||
Increase (Decrease) in Due to Related Parties, Total | $ (384,449) | 389,058 |
Series B Units [Member] | ||
Adjustments to reconcile net loss to net cash used by operating activities | ||
Consulting services paid by issuance of Series B units | $ 100,000 |
Organization and Nature of Plan
Organization and Nature of Planned Business: | 12 Months Ended |
Dec. 31, 2016 | |
GENERAL ORGANIZATION AND BUSINESS [Abstract] | |
Nature of Operations [Text Block] | Note 1 Organization and Nature of Planned Business : Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 5). On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $ 0.0001 The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date. As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.” As of March 6, 2017, we had approximately $ 24.1 |
Summary of Significant Accounti
Summary of Significant Accounting Policies: | 12 Months Ended |
Dec. 31, 2016 | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] | |
Significant Accounting Policies [Text Block] | Note 2 Summary of Significant Accounting Policies : The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation. December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175 Depreciation expense for the years ended December 31, 2016 and 2015 was $ 6,923 6,270 All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2016 and 2015. Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2016 and 2015. At December 31, 2016 and 2015, the number of shares underlying options and warrants that were anti-dilutive were approximately $ 6.9 4.5 Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing. The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation |
Contractual Commitments_
Contractual Commitments: | 12 Months Ended |
Dec. 31, 2016 | |
Contractual Commitments [Abstract] | |
Contractual Commitments [Text Block] | Note 3 Contractual Commitments : On September 4, 2014, the Company entered into a long-term lease for 4,000 The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options. 88,000 136,100 Pursuant to the Ramat Separation Agreement, Mr. Ramat received his current salary and benefits through the Termination Date, except that his salary was reduced by $ 10,000 200,000 50,000 In connection with the resignations of each of Mr. Freiman and Mr. Haft from the Board, the Company entered into a Director Separation Agreement, dated August 4, 2016, with each of Mr. Freiman and Mr. Haft (the “Director Separation Agreements”). Pursuant to such Director Separation Agreements, each of Mr. Freiman and Mr. Haft’s (i) outstanding unvested stock options, totaling 18,738 In addition, on August 4, 2016, the Company entered into a consulting agreement with SM Capital Management, LLC (“SMCM”), a limited liability company owned and controlled by Mr. Joshua Silverman (the “Consulting Agreement”). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM’s annual consulting fee is $ 120,000 |
Collaborative Agreements_
Collaborative Agreements: | 12 Months Ended |
Dec. 31, 2016 | |
Collaborative Agreements [Abstract] | |
Collaborative Agreements [Text Block] | Note 4 Collaborative Agreements : On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. During the year ended December 31, 2016, the Company paid Stanford the annual maintenance fee of $ 10,000 On January 19, 2017, the Company entered into a second license agreement with Stanford. See Footnote 10 “Subsequent Events” for additional information. On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company had agreed to pay fees to the CRO totaling $ 715,159 657,238 150,000 837,112 39,200 On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Services Agreement”) with WCT, effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2 clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD (the “Study”). Pursuant to the terms of the Services Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) Study subjects. The first Study site was initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, was approximately $ 11.6 200,000 On July 27, 2016, the Company received approval of the institutional review board (“IRB”) for its amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration (the “FDA”) relating to the Phase 2 clinical trial of the Company’s lead drug candidate, bryostatin-1, for the treatment of advanced AD, which amended protocol eliminates the second, exploratory, study period following the first 12 weeks of treatment. The primary objective is the assessment of safety and tolerability of bryostatin to occur at 13 weeks, which has not been changed with this amendment. The secondary objective is to assess efficacy, also at week 13. The amendment to cut the exploratory part of the study was made for business reasons in order to provide earlier completion of the study and for the planning of future studies. The changes to the study design were not due to any safety concerns. The cost savings from this amendment is approximately $ 2 On November 11, 2015, Neurotrope BioScience paid WCT $ 1,875,861 928,000 268,000 680,000 9.5 1.6 Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its CRE License Agreement (see Note 5 below). |
Related Party Transactions and
Related Party Transactions and Licensing / Research Agreements: | 12 Months Ended |
Dec. 31, 2016 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | Note 5 Related Party Transactions and Licensing / Research Agreements : As of December 31, 2016, James Gottlieb, a director of the Company, served as a director of CRE, and Shana Phares, also a director of the Company, served as President and Chief Executive Officer of CRE. William Singer was the president of CRE until April 26, 2016. CRE is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 3.9 Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “CRE License Agreement”). The CRE License Agreement amended and restated the TLSA, as amended. Under the terms of the CRE License Agreement, CRE provides research services and has granted Neurotrope BioScience the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the TLSA specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After the initial Series A Stock financing, the CRE License Agreement required Neurotrope BioScience to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. In addition, the CRE License Agreement requires the Company to pay CRE a “Fixed Research Fee” of $ 1 25,000,000 2 5 5 On November 12, 2015, Neurotrope BioScience, CRE, and NRV II entered into an amendment (the “Amendment”) to the TLSA pursuant to which CRE granted rights in certain technology to Neurotrope BioScience. Under the Amendment, the “Advances on Future Royalties” section of the TLSA was amended and restated to (i) eliminate the requirement that Neurotrope BioScience pay CRE prepaid royalties equal to five percent ( 5 2.5 Pursuant to the CRE License Agreement, on February 4, 2015, Neurotrope BioScience and CRE entered into a new Statement of Work and Account Satisfaction Agreement (the “February 2015 SOW”). The February 2015 SOW was effective as of October 1, 2014 and ended on September 30, 2015. In consideration for the February 2015 SOW, CRE agreed to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of CRE’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of CRE’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of CRE’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with CRE’s Investigative New Drug Application (“IND”) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKCε platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKCε activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for the purpose of developing a commercially usable PKCε activator. Under the CRE License Agreement, Neurotrope BioScience received a license to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of AD in humans (the “AD Diagnostic Test”). Further, under the February 2015 SOW, Neurotrope BioScience’s rights to the technology associated with the AD Diagnostic Test automatically reverted to CRE based on certain contractual conditions on July 10, 2015 and, accordingly, Neurotrope Bioscience no longer has any rights under the CRE License Agreement for diagnostic applications using the CRE patent portfolio or technology. The remaining terms and conditions of the CRE License Agreement, including the license of technology associated with Neurotrope BioScience’s PKC activator research (such as bryostatin), remain in full force and effect, in accordance with the conditions thereof. For the year ended December 31, 2015, Neurotrope BioScience incurred $ 2,052,595 14,558 On November 12, 2015, Neurotrope BioScience and CRE entered into a new statement of Work Agreement (the “November 2015 SOW Agreement”) pursuant to the TLSA. The November 2015 SOW Agreement is effective as of November 1, 2015 and continues until December 31, 2016. Pursuant to the November 2015 SOW Agreement, Neurotrope BioScience agreed to pay CRE $ 1,166,666 83,333 1 On July 28, 2016, CRE filed a petition for Chapter 11 Reorganization in the United States Bankruptcy Court for the Northern District of West Virginia. As part of the bankruptcy filing, CRE asked the Bankruptcy Court to reject certain executory contracts including employment agreements with a number of its researchers and other personnel, including, without limitation, Dr. Daniel Alkon, who is the Company’s Chief Scientific Officer and was also the former scientific director of CRE, and who led a team of CRE scientists who are involved on behalf of CRE in support of the Neurotrope-CRE License Agreement. CRE has not requested that the Neurotrope-CRE License Agreement itself be rejected. The Company does not believe that CRE, as a matter of law, has a right to terminate the Neurotrope-CRE License Agreement as a result of the bankruptcy filing and have been advised by CRE’s representatives that there will be no action regarding the Neurotrope-CRE License and that CRE intends to meet all of its obligations in support of the Company’s work. On September 23, 2016, the United States Bankruptcy Court for the Northern District of West Virginia entered an order approving the sale of a substantial amount of CRE's assets to West Virginia University. The Court also entered an order approving a settlement agreement between Dr. Alkon, CRE and West Virginia University. As part of the asset sale, CRE sold the BRNI name and all derivatives to West Virginia University. Consequently, the Board of CRE resolved on September 28, 2016 to change its name to Cognitive Research Enterprises, Inc. |
Income Taxes_
Income Taxes: | 12 Months Ended |
Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | Note 6 Income Taxes : The Company incurred a net operating loss for income tax purposes of approximately $ 32.5 11.0 1.1 Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company's ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since the Company's inception, due to the significant costs and complexities associated with such study. |
Common Stock_
Common Stock: | 12 Months Ended |
Dec. 31, 2016 | |
STOCKHOLDERS' EQUITY [Abstract] | |
Stockholders Equity Note Disclosure [Text Block] | Note 7 Common Stock: During the year ended December 31, 2016, all of the Company’s 262,349.4 0.0001 847,371 541,189 0.32 541,189 On April 12, 2016, the stockholders of the Company approved an increase in the number of authorized shares of Common Stock to 12,500,000 150 November 2016 Private Placement In a November 2016 private placement, the Company sold 3,828,754 12.80 6.40 24.5 In connection with the November 2016 Private Placement, on November 17, 2016, the Company filed with the Secretary of State of the State of Nevada an Amendment to its Certificate of Designations, Preferences and Rights of Series B Preferred Stock (the “Series B COD Amendment”), originally filed November 13, 2015 with the Secretary of State of the State of Nevada, as corrected by the Certificate of Correction filed November 19, 2015 with the Secretary of State of the State of Nevada (as so corrected, the “Certificate of Designation”). The Series B COD Amendment (i) provided that the Company’s entry into a binding securities purchase agreement, by and among the Company and the investors signatory thereto, in connection with a private placement of the Company’s common stock and warrants, that results in at least $ 8,000,000 18.56 255,450.4 825,812 Pursuant to the purchase agreement entered into in connection with November 2016 Private Placement, the Company agreed to reduce the exercise prices of certain of its outstanding warrants to purchase shares of common stock that were issued in connection with the November 2015 Private Placement. Effective as of November 18, 2016, the exercise price of each of the Series A Warrants and the Series C Warrants was reduced to $ 0.32 32.00 9.4 In connection with the Offering, pursuant to a Placement Agency Agreement, dated October 13, 2016 (the “Placement Agency Agreement”), among the Company, Katalyst Securities LLC and GP Nurmenkari Inc. (the “Placement Agents”), the Company has agreed to pay the Placement Agents (i) a cash fee at each closing under the Purchase Agreement equal to ten percent ( 10 10 6.40 Under the Placement Agency Agreement, the Company agreed to amend certain warrants previously issued to the Placement Agents. Immediately following the receipt of at least $8,000,000 of gross proceeds as part of the Offering, the exercise price of the 70,119 0.32 10,000,000 41,416 0.32 |
Stock Options_
Stock Options: | 12 Months Ended |
Dec. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] | |
Stock Option Note Disclosure [Text Block] | Note 8 Stock Options : The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 218,750 On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 93,750 312,500 Effective on November 21, 2016, the Company amended the 2013 Plan pursuant to an Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan (the “Equity Incentive Plan Amendment”) to increase the number of shares of Common Stock available for issuance under the Plan to 685,325 Option Grants Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 268,217 $ 42.24 7.5 $ 0 Options granted 424,390 $ 11.56 Less options forfeited (16,170) $ 20.29 Less options expired/cancelled (625) $ 56.32 Less options exercised - $ - Options outstanding at December 31, 2016 675,812 $ 23.54 8.9 $ 0 Options exercisable at December 31, 2016 436,357 $ 28.71 8.3 $ 0 In connection with the resignations of Mr. Ramat as President, Chief Executive Officer and director and of Mr. Freiman and Mr. Haft as directors, the Company entered into separation agreements, dated August 4, 2016, with each of Mr. Ramat, Mr. Freiman and Mr. Haft. Pursuant to such separation agreements, each of Mr. Ramat’s, Mr. Freiman’s and Mr. Haft’s (i) outstanding unvested stock options, totaling 40,511 500,000 Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.32 - $10.56 372,825 9.89 $ 10.56 191,392 $ 10.56 $19.20 - $22.72 60,647 9.24 $ 18.87 22,416 $ 19.42 $25.60 - $32.00 95,694 7.65 $ 29.83 82,289 $ 29.69 $35.52 - $49.60 35,003 7.41 $ 42.11 31,481 $ 41.46 $52.48 - $71.04 111,644 7.87 $ 58.22 108,779 $ 58.12 675,812 8.89 $ 43.52 436,357 $ 28.71 As of December 31, 2016, there were approximately $ 2.7 4.2 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options issued for the year ended December 31, 2016 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 87.50 2.250 9.17 The total stock option-based compensation recorded as operating expense was $ 2,804,527 922,934 |
Common and Preferred Stock Rese
Common and Preferred Stock Reserved for Future Issuances: | 12 Months Ended |
Dec. 31, 2016 | |
Common And Preferred Stock Reserved For Future Issuances [Abstract] | |
Common And Preferred Stock Reserved For Future Issuances [Text Block] | Note 9 Common and Preferred Stock Reserved for Future Issuances : Common Stock Reserved Common stock warrants outstanding 6,009,366 Common stock options outstanding 675,812 Total 6,685,178 On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 41,416 As of December 31, 2016, the Company is no longer required to reserve shares of Common Stock to accommodate up to an additional 50 Based upon the November 2016 Private Placement, the holders of 811,799 372,825 150 |
Subsequent Events_
Subsequent Events: | 12 Months Ended |
Dec. 31, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Note 10 Subsequent Events : Compensation Recommendation On January 4, 2017, based upon a recommendation by the compensation committee of the board of directors, the Company established the compensation for Dr. Daniel Alkon, M.D., who has served as President of the Company since September 23, 2016 and as the Company’s Chief Scientific Officer since August 2013. In consideration for his service as President, Dr. Alkon shall receive a salary of $ 25,000 75,000 Reverse Stock Split On January 11, 2017, the Company effected a 1-for-32 400,000,000 12,500,000 On February 17, 2017, the stockholders of the Company approved to increase the number of authorized shares of the Company’s Common Stock to 150 On January 19, 2017, the Company entered into a second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $ 70,000 10,000 2.1 1.5 4.5 Warrant Exercises From January 1, 2017 through March 6, 2017, 78 holders of 686,275 0.32 686,275 |
Summary of Significant Accoun17
Summary of Significant Accounting Policies: (Policies) | 12 Months Ended |
Dec. 31, 2016 | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents: The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment: December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175 Depreciation expense for the years ended December 31, 2016 and 2015 was $ 6,923 6,270 |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2016 and 2015. |
Earnings Per Share, Policy [Policy Text Block] | Earnings (Loss) Per Share: Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2016 and 2015. At December 31, 2016 and 2015, the number of shares underlying options and warrants that were anti-dilutive were approximately $ 6.9 4.5 |
Income Tax, Policy [Policy Text Block] | Income Taxes: Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing. |
Income Tax Uncertainties, Policy [Policy Text Block] | Risks and Uncertainties: The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock Compensation: The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements: In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation |
Summary of Significant Accoun18
Summary of Significant Accounting Policies: (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following: December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175 |
Stock Options_ (Tables)
Stock Options: (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | The following is a summary of stock option activity under the stock option plans for the year ended December 31, 2016: Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 268,217 $ 42.24 7.5 $ 0 Options granted 424,390 $ 11.56 Less options forfeited (16,170) $ 20.29 Less options expired/cancelled (625) $ 56.32 Less options exercised - $ - Options outstanding at December 31, 2016 675,812 $ 23.54 8.9 $ 0 Options exercisable at December 31, 2016 436,357 $ 28.71 8.3 $ 0 |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | The following is a summary of stock options outstanding under the plans as of December 31, 2016: Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.32 - $10.56 372,825 9.89 $ 10.56 191,392 $ 10.56 $19.20 - $22.72 60,647 9.24 $ 18.87 22,416 $ 19.42 $25.60 - $32.00 95,694 7.65 $ 29.83 82,289 $ 29.69 $35.52 - $49.60 35,003 7.41 $ 42.11 31,481 $ 41.46 $52.48 - $71.04 111,644 7.87 $ 58.22 108,779 $ 58.12 675,812 8.89 $ 43.52 436,357 $ 28.71 |
Common and Preferred Stock Re20
Common and Preferred Stock Reserved for Future Issuances: (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Common And Preferred Stock Reserved For Future Issuances [Abstract] | |
Schedule of Guarantor Obligations [Table Text Block] | Common stock reserved for future issuances consisted of the following at December 31, 2016 giving effect to the November 2016 Private Placement and February 17, 2017 shareholder vote described below: Common Stock Reserved Common stock warrants outstanding 6,009,366 Common stock options outstanding 675,812 Total 6,685,178 |
Organization and Nature of Pl21
Organization and Nature of Planned Business: (Details Textual) - USD ($) $ / shares in Units, $ in Millions | Mar. 06, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | |
Subsequent Event [Member] | |||
Cash, Cash Equivalents, and Short-term Investments | $ 24.1 |
Summary of Significant Accoun22
Summary of Significant Accounting Policies: (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 69,716 | $ 66,770 |
Accumulated depreciation | (14,518) | (7,595) |
Property and equipment, net | $ 55,198 | $ 59,175 |
Summary of Significant Accoun23
Summary of Significant Accounting Policies: (Details Textual) - USD ($) shares in Millions | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Summary Of Significant Accounting Policies [Line Items] | ||
Depreciation, Depletion and Amortization | $ 6,923 | $ 6,270 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 6.9 | 4.5 |
Maximum [Member] | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Property, Plant and Equipment, Useful Life | 10 years | |
Minimum [Member] | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years |
Contractual Commitments_ (Detai
Contractual Commitments: (Details Textual) | 1 Months Ended | 12 Months Ended | |
Aug. 31, 2016USD ($)shares | Dec. 31, 2016USD ($) | Sep. 04, 2014USD ($)ft² | |
Contractual Commitments And Contingencies [Line Items] | |||
Area of Land | ft² | 4,000 | ||
Description of Lessor Leasing Arrangements, Operating Leases | The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options. | ||
Accrued Rent | $ 88,000 | ||
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | $ 136,100 | ||
SM Capital Management LLC [Member] | |||
Contractual Commitments And Contingencies [Line Items] | |||
Management Fee Payable | $ 10,000 | ||
Monthly Consulting Fee Installments Payable | $ 120,000 | ||
Chief Executive Officer [Member] | |||
Contractual Commitments And Contingencies [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 10 years | ||
Management Fee Payable | $ 50,000 | ||
Supplemental Unemployment Benefits, Severance Benefits | $ 200,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 21,877 | ||
Management [Member] | |||
Contractual Commitments And Contingencies [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 10 years | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 18,738 | ||
Maximum [Member] | |||
Contractual Commitments And Contingencies [Line Items] | |||
Increase (Decrease) in Accrued Salaries | $ 23,333 | ||
Minimum [Member] | |||
Contractual Commitments And Contingencies [Line Items] | |||
Increase (Decrease) in Accrued Salaries | $ 10,000 |
Collaborative Agreements_ (Deta
Collaborative Agreements: (Details Textual) - USD ($) | Nov. 11, 2015 | Oct. 09, 2015 | May 15, 2014 | Jun. 30, 2016 | Nov. 19, 2014 | Dec. 31, 2016 |
Collaborative Agreements [Line Items] | ||||||
Estimated Budget For Services | $ 11,600,000 | |||||
Payments for Advance to Affiliate | $ 1,875,861 | $ 200,000 | ||||
Service Fees | 928,000 | |||||
Pass Through Expenses | 268,000 | |||||
Investigator And Institute fees | 680,000 | |||||
Clinical Trial, Amended Protocol, Cost savings | $ 2,000,000 | |||||
July 2016 Through September 2017 [Member] | ||||||
Collaborative Agreements [Line Items] | ||||||
Estimated Budget For Services | $ 9,500,000 | |||||
Contract Research Organization [Member] | ||||||
Collaborative Agreements [Line Items] | ||||||
Commitment To Pay Fees | $ 715,159 | $ 150,000 | ||||
Reduction Of Commitment Fees | $ 657,238 | |||||
Payments for Fees | $ 837,112 | |||||
Worldwide Clinical Trials [Member] | ||||||
Collaborative Agreements [Line Items] | ||||||
Prepaid Expense | 1,600,000 | |||||
Stanford Agreement [Member] | ||||||
Collaborative Agreements [Line Items] | ||||||
Annual License Maintenance Fee | 10,000 | |||||
Mount Sinai Agreement [Member] | ||||||
Collaborative Agreements [Line Items] | ||||||
License Initiation Fee | $ 39,200 |
Related Party Transactions an26
Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |
Nov. 12, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | |
Related Party Transaction [Line Items] | |||
Technology Services Costs | $ 2,052,595 | ||
Research and Development Expense, Total | $ 5,603,989 | 2,180,263 | |
Due to Related Parties, Current | 4,609 | $ 389,058 | |
BRNI License Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Due to Related Parties, Current | $ 1,166,666 | ||
Service Fees Third Party | $ 83,333 | ||
Due to Related Parties | 14,558 | ||
November 2015 Sow Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Related Party Transaction, Purchases from Related Party | 1,000,000 | ||
Blanchette Rockefeller Neurosciences Institute [Member] | |||
Related Party Transaction [Line Items] | |||
Royalties Percentage | 5.00% | ||
Post PA Fee Proceeds Percent | 2.50% | ||
Fixed Research Fee [Member] | |||
Related Party Transaction [Line Items] | |||
Research and Development Expense, Total | $ 1,000,000 | ||
Services Reimbursement [Member] | |||
Related Party Transaction [Line Items] | |||
Royalties Percentage | 5.00% | ||
Services Reimbursement [Member] | Minimum [Member] | |||
Related Party Transaction [Line Items] | |||
Royalties Percentage | 2.00% | ||
Services Reimbursement [Member] | Maximum [Member] | |||
Related Party Transaction [Line Items] | |||
Royalties Percentage | 5.00% | ||
Series B Preferred Stock [Member] | Fixed Research Fee [Member] | |||
Related Party Transaction [Line Items] | |||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 25,000,000 | ||
President [Member] | |||
Related Party Transaction [Line Items] | |||
Equity Method Investment, Ownership Percentage | 3.90% |
Income Taxes_ (Details Textual)
Income Taxes: (Details Textual) $ in Millions | 50 Months Ended |
Dec. 31, 2016USD ($) | |
Income Tax Expenses Benefit [Line Items] | |
Operating Income (Loss) | $ 32.5 |
Deferred Tax Assets, Gross, Current | 11 |
Deferred Tax Assets, Net | $ 1.1 |
Common Stock_ (Details Textual)
Common Stock: (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||
Nov. 30, 2016 | Nov. 23, 2016 | Nov. 18, 2016 | Nov. 17, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Feb. 17, 2017 | Jan. 02, 2017 | |
Class of Stock [Line Items] | ||||||||
Common Stock, Shares Authorized | 12,500,000 | 12,500,000 | ||||||
Deemed Dividend Payable | $ 9,400,000 | $ 9,396,311 | $ 0 | |||||
Series A Warrant [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 | |||||||
Series C Warrant [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 0.32 | |||||||
Series E Warrant [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 32 | |||||||
November 2016 Private Placement [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 12.80 | |||||||
Stock Issued During Period, Shares, New Issues | 3,828,754 | |||||||
Shares Issued, Price Per Share | $ 6.40 | |||||||
Proceeds from Issuance of Private Placement | $ 24,500,000 | |||||||
Class Of Warrant Or Right, Expiration Term | 5 years | |||||||
Placement Agency Agreement [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.40 | |||||||
Proceeds from Issuance of Private Placement | $ 10,000,000 | |||||||
Class Of Warrant Or Right, Expiration Term | 5 years | |||||||
Private placement Agent Fee Percentage | 10.00% | |||||||
Warrant To Purchase Common Stock Percentage | 10.00% | |||||||
Placement Agency Agreement [Member] | Series B Broker Warrants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 | |||||||
Class Of Warrant Or Right, Expiration Term | 6 months | |||||||
Class of Warrant or Right, Outstanding | 70,119 | |||||||
Placement Agency Agreement [Member] | Series A Broker Warrants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 | |||||||
Class of Warrant or Right, Outstanding | 41,416 | |||||||
Subsequent Event [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Common Stock, Shares Authorized | 150,000,000 | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 686,275 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 | |||||||
Series B Convertible Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Conversion of Stock, Shares Converted | 262,349.4 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.0001 | |||||||
Series B COD Amendment [Member] | November 2016 Private Placement [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Conversion of Stock, Shares Converted | 255,450.4 | |||||||
Convertible Preferred Stock, Shares Issued upon Conversion | 825,812 | |||||||
Proceeds from Issuance of Private Placement | $ 8,000,000 | |||||||
Common Stock Conversion Price | $ 18.56 | |||||||
Common Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Stock Issued During Period, Shares, New Issues | 3,828,754 | |||||||
Neurotrope Inc. [Member] | Common Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Convertible Preferred Stock, Shares Issued upon Conversion | 847,371 | |||||||
Warrants Exercisable | 541,189 | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 541,189 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 |
Stock Options_ (Details)
Stock Options: (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of Shares, Outstanding | 268,217 | |
Number of Shares, Options granted | 424,390 | |
Number of Shares, Less options forfeited | (16,170) | |
Number of Shares, Less options expired/cancelled | (625) | |
Number of Shares, Less options exercised | 0 | |
Number of Shares, Outstanding | 675,812 | 268,217 |
Number of Shares, Options exercisable | 436,357 | |
Weighted-Average Exercise Price, Outstanding | $ 42.24 | |
Weighted-Average Exercise Price, Options granted | 11.56 | |
Weighted - Average Exercise Price, Options terminated | 20.29 | |
Weighted-Average Exercise Price, Options, Less options expired/cancelled | 56.32 | |
Weighted-Average Exercise Price, Options exercised | 0 | |
Weighted-Average Exercise Price, Outstanding | 23.54 | $ 42.24 |
Weighted-Average Exercise Price, Options exercisable | $ 28.71 | |
Weighted-Average Remaining Contractual Term, Outstanding (in years) | 8 years 10 months 24 days | 7 years 6 months |
Weighted-Average Remaining Contractual Term, Exercisable (in years) | 8 years 3 months 18 days | |
Aggregate Intrinsic Value, Outstanding | $ 0 | $ 0 |
Aggregate Intrinsic Value, Exercisable | $ 0 |
Stock Options_ (Details 1)
Stock Options: (Details 1) - $ / shares | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 675,812 | 268,217 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 years 3 months 18 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 23.54 | $ 42.24 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 436,357 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 28.71 | |
Exercise Price Range One [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | 0.32 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ 10.56 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 372,825 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 9 years 10 months 20 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 10.56 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 191,392 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 10.56 | |
Exercise Price Range Two [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | 19.20 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ 22.72 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 60,647 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 9 years 2 months 26 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 18.87 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 22,416 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 19.42 | |
Exercise Price Range Three [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | 22.60 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ 32 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 95,694 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 7 years 7 months 24 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 29.83 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 82,289 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 29.69 | |
Exercise Price Range Four [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | 35.52 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ 49.60 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 35,003 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 7 years 4 months 28 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 42.11 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 31,481 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 41.46 | |
Exercise Price Range Five [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | 52.48 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ 71.04 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 111,644 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 7 years 10 months 13 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 58.22 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 108,779 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ 58.12 |
Stock Options_ (Details Textual
Stock Options: (Details Textual) - USD ($) | Aug. 04, 2016 | Jul. 23, 2014 | Dec. 31, 2016 | Dec. 31, 2015 | Aug. 31, 2016 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 87.50% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.25% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 9.17 | ||||
Employee Benefits and Share-based Compensation | $ 2,804,527 | $ 722,934 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 2,700,000 | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 4 years 2 months 12 days | ||||
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost | $ 500,000 | ||||
Management [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | 18,738 | ||||
Management [Member] | Separation Agreements [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | 10 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | 40,511 | ||||
Equity Incentive Plan 2013 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 218,750 | ||||
Equity Incentive Plan 2013 [Member] | Maximum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 312,500 | ||||
Equity Incentive Plan 2013 [Member] | Minimum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 93,750 | ||||
Equity Incentive Plan Amendment [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 685,325 |
Common and Preferred Stock Re32
Common and Preferred Stock Reserved for Future Issuances: (Details) | Dec. 31, 2016shares |
Class of Stock [Line Items] | |
Common Stock Reserved | 6,685,178 |
Common stock warrants outstanding [Member] | |
Class of Stock [Line Items] | |
Common Stock Reserved | 6,009,366 |
Common stock options outstanding [Member] | |
Class of Stock [Line Items] | |
Common Stock Reserved | 675,812 |
Common and Preferred Stock Re33
Common and Preferred Stock Reserved for Future Issuances: (Details Textual) - shares | Feb. 09, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Feb. 17, 2017 |
Percentage of shares Reserved for Potential Dilution | 50.00% | |||
Conversion of Stock, Shares Issued | 11,814,874 | 18,524,163 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 675,812 | 268,217 | ||
Common Stock, Shares Authorized | 12,500,000 | 12,500,000 | ||
Subsequent Event [Member] | ||||
Common Stock, Shares Authorized | 150,000,000 | |||
Nov 2016 Private Placement [Member] | ||||
Class of Warrant or Right, Outstanding | 811,799 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 372,825 | |||
Warrant Holder [Member] | ||||
Conversion of Stock, Shares Issued | 41,416 | |||
Series A Preferred Stock [Member] | Warrant Holder [Member] | ||||
Conversion of Stock, Shares Converted | 1,325,000 |
Subsequent Events_ (Details Tex
Subsequent Events: (Details Textual) - USD ($) | Jan. 11, 2017 | Jan. 04, 2017 | Jan. 02, 2017 | Jan. 19, 2017 | Dec. 31, 2016 | Feb. 17, 2017 | Dec. 31, 2015 |
Subsequent Event [Line Items] | |||||||
Common Stock, Shares Authorized | 12,500,000 | 12,500,000 | |||||
Scenario, Previously Reported [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common Stock, Shares Authorized | 400,000,000 | ||||||
Stanford Agreement [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Annual License Maintenance Fee | $ 10,000 | ||||||
Subsequent Event [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 686,275 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.32 | ||||||
Stockholders' Equity, Reverse Stock Split | 1-for-32 | ||||||
Common Stock, Shares Authorized | 150,000,000 | ||||||
Stock Issued During the Period, Stock Warrants Exercised | 686,275 | ||||||
Subsequent Event [Member] | Stanford Agreement [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Annual License Maintenance Fee | $ 10,000 | ||||||
Commitment To Pay Fees | 2,100,000 | ||||||
License Costs | $ 70,000 | ||||||
Subsequent Event [Member] | Maximum [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Royalty Payment Percentage | 4.50% | ||||||
Subsequent Event [Member] | Minimum [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Royalty Payment Percentage | 1.50% | ||||||
President [Member] | Subsequent Event [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Compensation | $ 25,000 | ||||||
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount | $ 75,000 |